A Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride in Gastroscopy/Colonoscopy

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2024

Conditions
GastroscopyColonoscopy
Interventions
DRUG

ET-26HCl 0.6mg/kg group

The initial dose is 0.6 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion). Infusion time was 1minute ± 5second.

DRUG

ET-26HCl 0.8mg/kg group

The initial dose is 0.8 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion). Infusion time was 1minute ± 5second.

DRUG

Etomidate Injectable Product 0.3mg/kg group

The initial dose is 0.3 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion).Infusion time was 1minute ± 5second.

Trial Locations (3)

628017

Guangyuan First People's Hospital, Guangyuan

644000

Yibin Second People's Hospital, Yibin

Unknown

Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital, Chengdu

Sponsors
All Listed Sponsors
lead

Ahon Pharmaceutical Co., Ltd.

OTHER

NCT06682546 - A Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride in Gastroscopy/Colonoscopy | Biotech Hunter | Biotech Hunter